Abogen Biosciences and Ruijin Hospital Establish Joint Nucleic Acid Therapeutics Institute to Accelerate Clinical Translation of mRNA Drugs

On November 26, 2024, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine (hereinafter referred to as "Ruijin Hospital") and Abogen held the unveiling ceremony of the "Ruijin-Abogen Nucleic Acid Drug Research Institute" in Suzhou Industrial Park, jointly announcing the official establishment of the institute.

The institute aims to further explore the application of mRNA drugs in cancer and autoimmune diseases, and comprehensively accelerate the innovation and clinical translation of mRNA drugs. This follows the previous collaboration between the two parties inAnother milestone event following the signing of the strategic cooperation agreement in June this year,Marks the entry of Ruijin Hospital and Abogen's collaboration into the practical implementation phase.。

Accelerated Transformation:The institute will promote the acceleration of clinical translation and research progress for both parties.

The institute will promote closer exchange and cooperation between the two parties, starting from clinical needs, to accelerate the transformation of scientific research achievements and the development of new products. As Ms. Song Wenjie, Chief Medical Officer of Abogen, introduced earlier this year,6Following the signing of the strategic agreement in [Month], multiple projects have entered investigator-initiated clinical studies (IIT), covering areas such as lung cancer, pancreatic cancer, and colorectal cancer, especially targeting泛KRASMutatedmRNATumor vaccine, ismRNAAnother Disruption of Traditional "Undruggable" Targets by Technology.

In11Month26The unveiling ceremony held on the dayShen Baiyong, Professor and Vice President of Ruijin Hospital (Executive Dean of the Academy）and Ms. Song Wenjie, Chief Medical Officer of Abogen (Executive Vice Dean of the Academy), represented both parties at the unveiling ceremony. Ning Guang, Academician of the Chinese Academy of Engineering and President of Ruijin Hospital (Honorary President of the Institute), Founder, Chairman and CEO of Abogen, Dr. Ying Bo (Executive Dean of the Institute），Mr. Ni Qian, Member of the Working Committee and Deputy Director of the Management Committee of Suzhou Industrial Park, and Mr. Yin Jianguo, Chairman of Suzhou Industrial Park Biotech Development Co., Ltd.Witnessed the unveiling ceremony.

Collaborative Innovation: The Research Institute Will Lead a New Chapter in the Integration of Technology and Industry

The unveiling ceremony attracted numerous heavyweight leaders and representatives from enterprises, hospitals, government, and the investment community to jointly witness Abogen Biosciences asmRNAThe leading unicorn enterprise in the field has joined forces with Ruijin Hospital, a top medical institution in China.

Ruijin Hospital President Ning Guang, an academician, and Dr. Ying Bo, founder of Abogen, both expressed high recognition of the strong partnership and close collaboration between the two parties in their speeches. Academician Ning mentionedmRNAVaccine ormRNATreatment Technology: The Next Big Breakthrough in Medicine。mRNATechnology will bring breakthroughs to medical treatment, so finding a suitable partner is crucial. Dr. Ying Bo sincerely acknowledged the innovative concept of "from clinical practice to the laboratory and back to clinical validation" at Ruijin Hospital, which provides a solid application and practice platform for the development of Abogen's new technologies.Deeply honored to collaborate with Ruijin Hospital to accelerate the development of nucleic acid drugs that are "patient-centered and clinically oriented."。

Academician Ning also particularly emphasized that the most important task after the establishment of the institute isWhether a really good research direction with the possibility of becoming a drug can be found. If found, everyone must put forth their full effort.Solidly and steadily, with early results.

The institute is located at the headquarters of Abogen Biosciences in Suzhou. This event also invited local government leaders, with Mr. Ni Qian, member of the Working Committee of Suzhou Industrial Park and Deputy Director of the Management Committee, delivering a speech. Mr. Ni mentionedThe establishment of the institute is not only an important step for Ruijin Hospital and Abogen to leverage their respective strengths for industry-medical integration and collaborative innovation, but also a strong support for the development of Suzhou Industrial Park's biopharmaceutical industry.And expressed that the park will continue to provide full support and services as always, creating the best environment for the development of the institute.

Dr. Abogen's Speech

Speech by Academician Ning Guang

Director Ni Qian's Speech

Also attending the unveiling ceremony were Professor Yang Chengde, Director of the Department of Rheumatology and Immunology at Ruijin Hospital, Professor Zou Duowu, Director of the Department of Gastroenterology, Mr. Cui Wenguo, Director of the Department of Science and Technology Development, along with other department directors, experts, and leaders from the Department of Science and Technology Development; Mr. Wang Xie, Vice President of Suzhou Industrial Park Biotech Development Co., Ltd., Mr. Zhou Jun, Executive Dean of Shanghai Jiaotong University Suzhou Innovation Institute, among other experts.

A development philosophy guided by clinical value and centered on patient needs, has become a common consensus in current drug development. "Ruijin-Abogen Nucleic Acid Drug Research Institute" will rely on Abogen's industry-leading and comprehensivemRNAThe technology platforms related to drug development, along with Ruijin Hospital's innovation chain "from clinical practice to the laboratory and back to clinical validation," are accelerating the research and clinical translation of nucleic acid drugs and will play a greater role in leading the integration of technology and industry.

Related Reading

Abogen Biosciences Signs Strategic Cooperation Agreement with Ruijin Hospital

About Us

Abogen Biosciences Co., Ltd. (Abbr. "Abogen") is an innovative biopharmaceutical company focused on the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary mRNA and nanodelivery technology platforms and is one of the few mRNA drug research and development enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development, to large-scale production. The company has established a rich product pipeline, spanning multiple fields including infectious disease prevention and control (such as the mRNA COVID-19 vaccine), cancer immunotherapy, protein replacement therapy, and more.